エピソード

  • AMGN Today - Aug 13: Steady Day for Amgen

    AMGN Today - Aug 13: Steady Day for Amgen
    2026/08/13
    Hey there! It’s Joey here, your friendly long-time investor, breaking down the day’s action. Today we’re talking about Amgen, and guess what? It had a pretty chill day, barely moving up by 0.38%.

    So, what went down? Amgen’s stock price closed at around 417.75. Yeah, not a wild ride at all—just kind of floated along. Volume was steady, matching its average, which means folks weren’t rushing to buy or sell like crazy. It’s like everyone was just hanging out, not too worried.

    Now, why did it stay so steady? Well, there’s some chatter about Amgen’s recent performance. They posted strong Q2 results and even raised their guidance for 2026. That’s usually a good sign, right? But here’s the kicker: some analysts are saying it might be fully valued now. So, while the numbers look solid, there’s a bit of caution in the air. People are trying to figure out if it’s worth chasing after or if it’s already priced in. Also, Daiwa Securities just bumped their price target to $430 from $390, which is a bit of a boost, but again, it’s all about how investors feel about that valuation.

    Oh, and just a little nugget for you—Tema ETFs just increased their stake in Amgen. So, some folks are still feeling good about it, even if the stock’s taking a breather today.

    That’s the scoop! Amgen’s playing it cool, and while there’s some optimism with the earnings and guidance, there’s also that nagging feeling about whether it’s peaked. Just remember, this is all for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 12: Small Move, Some Buzz

    AMGN Today - Aug 12: Small Move, Some Buzz
    2026/08/12
    Hey there! It’s Joey here, your friendly market buddy, and I’m breaking down the day for you. Today, we’re talking about Amgen, and it was a pretty chill day on the stock front—closed up just a smidge, like 0.2%. Not exactly a wild ride, but hey, a win's a win, right?

    So, what went down? Amgen started off the day with some solid trading, but honestly, it felt like a slow bleed for most of it. It didn’t really pop off, but it didn’t crash either. Just kind of hung around that $415 mark. You know those days where you’re just waiting for something to happen? Yeah, that was today.

    Now, let’s talk about why. There’s been some chatter in the air lately. Tema ETFs decided to up their stake in Amgen, which is usually a good sign. Plus, one of the directors, Charles Holley, got a stock award and reported his trust holdings. That kind of insider action can spark some interest. Also, G&S Capital jumped in with a fresh investment of about $1.58 million. So, there’s definitely some buzz around the stock, but it didn’t translate into a big move today.

    On the horizon, Amgen’s Q2 earnings call had some analysts asking some pretty interesting questions. Those calls can be a goldmine for info, so keep an ear out for that if you’re following the stock.

    Alright, that’s a wrap for today! Just remember, this is all for fun and to keep you in the loop—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 11: Mixed Signals in the Market

    AMGN Today - Aug 11: Mixed Signals in the Market
    2026/08/11
    Hey there! It’s Joey here, your friendly investor buddy, breaking down the day’s action. Today, we’re talking about Amgen, and it was a bit of a red day. The stock dipped about three bucks, which is a small hit, right?

    So, what happened? Amgen slid down by 0.75%. It didn’t really catch a break today, even though it wasn’t a crazy drop. The trading volume was right on average, so it wasn’t like everyone was panicking or anything. Just a slow bleed, you know?

    Now, why did it happen? Well, there were a few things buzzing around. First off, there's chatter about Charles Schwab Trust upping their stake in Amgen. That usually sounds like good news, but it didn’t really light a fire under the stock. Then, there’s the news about Amgen’s director, Charles Holley, getting a stock award and reporting his holdings. Again, cool stuff for insiders, but it didn’t seem to move the needle for everyone else.

    On the flip side, Guggenheim raised Amgen’s price target to $388, which is a positive sign. But honestly, it feels like the market is just digesting all this info without any big reactions. So, nobody really knows why it got smoked today. Just one of those days, I guess.

    Looking ahead, Amgen’s Q2 earnings call had some solid analyst questions, so there’s definitely some interest in what they’re doing. That could be something to keep an eye on, especially if they drop any juicy details.

    Alright, that’s a wrap for today! Just remember, this is all for fun and info – not financial advice. Stay chill and invest smart! Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 10: Guggenheim Raises Price Target

    AMGN Today - Aug 10: Guggenheim Raises Price Target
    2026/08/10
    Hey there! It’s Joey, your friendly investor buddy, here to break down today’s action for Amgen, ticker AMGN. So, today was a bit of a snooze fest for the stock, barely moving and closing down just a smidge—0.2%. Not exactly fireworks, right?

    Here’s what happened. Amgen had a pretty chill day, with trading volume right in line with its average. No big swings or wild moves. It’s like everyone was just sitting back, sipping their coffee, and waiting for something to happen.

    Now, why the slow day? Well, there’s a mix of stuff going on. Guggenheim just raised their price target for Amgen to $388, thanks to a strong quarter. That’s a good sign, but it seems like investors are still processing all the news from the past week. Amgen jumped about 8% earlier this week after they raised their guidance, which got folks excited. But then, Erste Group Bank came in and lowered their earnings estimates, which kinda threw a wet blanket on the party. So, it’s a bit of good news and bad news swirling around. Nobody really knows why it didn’t pop today, but sometimes the market just does its own thing.

    Looking ahead, there’s chatter about Amgen’s pipeline updates. They’re working on some promising stuff that could shake things up in the future. So, that’s something to keep an eye on.

    Alright, that’s a wrap for today’s Amgen scoop! Just remember, I’m here for the info and good vibes, not to give financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 09: EMA Backs Repatha Use

    AMGN Today - Aug 09: EMA Backs Repatha Use
    2026/08/09
    Hey there! It’s Joey, your friendly long-time investor here, breaking down the day for you. Today, we’re talking about Amgen, and guess what? It was a green day! The stock was up about 1.5%. Not a huge jump, but still nice to see some green.

    So, what went down today? Amgen's stock had a bit of a bounce thanks to some positive news. The big highlight? The European Medicines Agency gave a thumbs up for broader use of their drug Repatha in high-risk patients. That’s a big deal, right? When a regulatory body backs a product, it can really pump some confidence into the stock.

    Now, why the buzz? Well, this EMA nod could open up a whole new market for Repatha, which is already used to lower cholesterol. Analysts are getting excited too and have been hiking their price targets for the stock. It’s like when your favorite band drops a surprise album — it just gets everyone hyped up.

    But it wasn’t all sunshine and rainbows today. There was some news that Nancy Grygiel, Amgen’s Senior VP and Chief Commercial Officer, sold off about $1.19 million worth of stock. That one stung a bit for investors. When insiders sell, people start to wonder what they know that we don’t. But hey, maybe it’s just a personal financial move. Who knows?

    Looking ahead, Amgen’s got to keep that momentum going. They’ve had some solid earnings recently and updates on their pipeline, so there’s a lot to watch. But for now, it’s all about that EMA approval and the potential it brings.

    Alright, that’s the scoop for today! Just remember, this is all for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 08: EMA Backs Repatha Use

    AMGN Today - Aug 08: EMA Backs Repatha Use
    2026/08/08
    Hey there! I’m Joey, your friendly stock enthusiast, breaking down the day’s action. So today we’re talking about Amgen, and it was a green day, up about 1.5%. Not too shabby!

    So, what went down? Amgen popped up after some good news from the European Medicines Agency. They gave a thumbs up for broader use of Amgen's heart drug Repatha in high-risk patients. That’s always a boost for a company when regulators back their products. People were feeling it, and the stock got some nice momentum.

    Now, here’s where it gets interesting. While the good news was rolling in, there were also some mixed signals. One of Amgen's top execs, Nancy Grygiel, sold off over a million bucks worth of stock. That’s a big move, and it kinda makes people raise an eyebrow. Is she cashing in before something changes? Who knows, but it definitely had some folks hitting the sell button. Also, we saw some changes in holdings with other firms. Teamwork Financial Advisors sold off a chunk, while MRA Advisory Group decided to grab more shares. It’s like a tug-of-war with the stock!

    Looking ahead, Amgen’s got some more eyes on it since the Repatha news. Investors will be watching closely to see how that plays out in the next earnings report.

    To wrap this up, Amgen had a decent day thanks to solid news about Repatha, but there’s also some caution in the air with those insider sales. Just remember, this is all for your info and fun—no buy or sell tips from me. Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 07: Sales View Boosted by $1B

    AMGN Today - Aug 07: Sales View Boosted by $1B
    2026/08/07
    Hey there! It’s Joey, your friendly investor here, breaking down the day for Amgen, or AMGN as the cool kids say. Today was a green day for Amgen, with the stock inching up about 0.34%. Not a massive leap, but hey, we'll take it!

    So, what happened? Well, Amgen’s stock got a nice little bump after they announced some big news. They raised their sales outlook by a cool billion bucks! That’s right, they smashed expectations, and that always gets people excited. When a company shows it’s doing better than we thought, investors usually start feeling a bit more optimistic.

    Now, why did this happen? The buzz is all about Amgen’s drug growth. They’ve been rolling out some new treatments, and it looks like those are really hitting the mark. Even with some setbacks in the obesity treatment space—yeah, that one stung—they still managed to keep things moving in the right direction. Basically, their performance outpaced those bumps in the road, which is a big deal. Plus, RBC jumped in and raised their price target to $400, so that’s got to feel good for the folks holding the stock.

    Oh, and here’s something to keep in mind: the Czech National Bank just grabbed some shares of Amgen. That’s usually a sign that institutional investors are liking what they see, which could mean more confidence in the stock.

    So, to wrap it up, Amgen had a solid day, boosted by a raised sales outlook and some positive drug growth news. Always nice to see a company doing well, right? Remember, this is just for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • AMGN Today - Aug 06: Sales View Boosted

    AMGN Today - Aug 06: Sales View Boosted
    2026/08/06
    Hey there! I’m Joey, your friendly stock enthusiast. I’ve been investing for a while now, and I’m here to break down the day for you. Today, we’re talking about Amgen, and it was a bit of a red day—down about 1.2%.

    So, here’s the scoop. Amgen kicked off the day strong but ended up slipping a bit. They had some big news about their sales outlook, which initially got folks excited, but it looks like some people decided to cash in those gains by the end of the day.

    Now, why the mixed vibes? Amgen just raised their sales forecast by a whopping $1 billion after absolutely crushing expectations in their latest earnings report. That’s some solid news, right? But it seems like investors are also feeling a little cautious. There’s chatter about potential risks looming over the stock, especially with their obesity drug facing some setbacks. So, while the growth is impressive, it’s like people are saying, “Yeah, that’s great, but what’s next?”

    Looking ahead, Amgen has a lot of eyes on them with their ongoing innovations. They’re trying to push through some new drugs that could really shake things up in the market. That’s definitely something to keep an ear out for!

    So, there you have it! Amgen had a bit of a rollercoaster day, but they’ve got some exciting stuff in the pipeline. Remember, I’m just here sharing info and having fun with this stock stuff, not giving financial advice. Catch you later!
    続きを読む 一部表示
    1 分